Of all the BRAF mutations, BRAF-V600E is the most frequent.

This condition, also known as familial hypercalciuric hypocalcemia, is the result of a heterozygous activating mutation of the calcium-sensitive receptor.

In vitro, imatinib inhibits proliferation and induces apoptosis in gastrointestinal stromal tumour (GIST) cells, which express an activating kit mutation.

In vitro, imatinib inhibits proliferation and induces apoptosis in gastrointestinal stromal tumour (GIST) cells, which express an activating kit mutation.

In vitro, imatinib inhibits proliferation and induces apoptosis in gastrointestinal stromal tumor (GIST) cells, which express an activating c-kit mutation.

In vitro, imatinib inhibits proliferation and induces apoptosis in gastrointestinal stromal tumor (GIST) cells, which express an activating c-kit mutation.

A method of treating NSCLC comprising in some aspects administering OSI-906 and an EGFR inhibitor to a patient having NSCLC having an activating EGFR mutation, as disclosed herein.

Based on the results of the IUNO study, Tarceva is no longer indicated for maintenance treatment after first-line treatment in patients without an EGFR-activating mutation.

We have previously looked at what happens when PIK3CA is inactivated, but here we saw that an activating mutation in this gene can lead to a dramatic overgrowth of blood vessels.

We have previously looked at what happens when PIK3CA is inactivated, but here we saw that an activating mutation in this gene can lead to a dramatic overgrowth of blood vessels.

Measurement of serum tryptase shows values consistently above 20ng/mL, and the search for activating mutations of KIT is positive in the vast majority of cases.

Of all the BRAF mutations, BRAF-V600E is the most frequent.

The present invention also relates to a mutation in enhancer II region at position 1752 of the virus sequence which reduces the binding affinity of hnRNP K with the enhancer II region.

A recurrent somatic mutation, L265P in the MYD88 gene has been reported to occur in over 90% of WM patients.

A highly recurrent MYD88 (3p22) somatic mutation (L265P) has recently been identified in 90% of WM patients.